Incorporating Digital Biomarkers & Endpoints Into Clinical Trials: Key Regulatory Considerations

As technology advances and innovations like digital endpoints and biomarkers become more prevalent, regulatory considerations surrounding them become more complex. Navigate this evolving space, with insights from this free webinar.

Experts from Biofourmis will share their insights into:

Traditional vs. digital measures in clinical research and their key differences.
Regulatory framework for digital biomarkers and endpoints, including regional disparities.
Regulatory considerations for data integrity and security, validation and reliability, and patient safety and privacy.
Integrating digital biomarkers and endpoints into trial protocols.
Emerging and current regulatory trends and future regulatory direction.

Sign up to our content service and access now

Your company email address

Please select your industry: (max 1)
Ask a question early:

Opt In?

By you requesting this resource, you agree to our terms of use. All data is protected by our Privacy Notice. You can change your contact preferences here. If you have any further questions please get in contact.
Citeline (previously Pharma Intelligence UK) may contact me with updates, relevant promotions and information about products. My Information will be used in accordance with the Citeline Privacy Policy, and you withdraw your permission to receive any of our communications at any time.
By clicking submit, you consent to allow Biofourmis to store and process the information submitted to provide you the content requested. They are subject to Biofourmis's Terms and Conditions.

Incorporating Digital Biomarkers & Endpoints Into Clinical Trials: Key Regulatory Considerations

Sign up to our content service and access now

Opt In?

Explore similar content

Resiliency and innovation - Navigating the current biotech landscape

Immune checkpoint inhibitors: A breakthrough for immunotherapy

HIV – Global Clinical Trial Landscape